Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units

Transfusion

Volumn 48, Issue 8, 2008, Pages 1685-1692

  Picker, Susanne M ^a   Steisel, Alexander ^a   Gathof, Birgit S ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; PADGEM PROTEIN; RIBOFLAVIN; RISTOCETIN;

AEROBIC METABOLISM; APHERESIS; ARTICLE; CONTROLLED STUDY; GAMMA IRRADIATION; GLUCOSE INTAKE; HUMAN; IN VITRO STUDY; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; OXYGEN CONSUMPTION; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE PRESERVATION; UPREGULATION;

BACTEREMIA; BLOOD COMPONENT REMOVAL; BLOOD PLATELETS; BLOOD PRESERVATION; CELL SURVIVAL; GAMMA RAYS; GLUCARIC ACID; HUMANS; L-LACTATE DEHYDROGENASE; LACTATES; PLATELET AGGREGATION; PLATELET COUNT; PLATELET TRANSFUSION; PSORALENS; RIBOFLAVIN;

EID: 48249083843     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01778.x     Document Type: Article

References (48)

1. Blajchman MA, Goldman M, Baeza F. Improving the bacteriological safety of platelet transfusion. Transfus Med Rev 2004 18 : 11 24.
2. Goodrich L, Douglas I, Urioste M. Riboflavin photoinactivation procedure inactivates significant levels of bacteria and produces a culture negative product. Transfusion 2002 42 : 16S.
3. Goodrich L, Ghielli M, Hansen E, Woolum M, Gampp D, Goodrich R, Keil S. Riboflavin and UV light inactivate enveloped and non-enveloped viruses in platelet concentrates under conditions which maintain cell quality. Vox Sang 2002 83 : 111.
4. Goodrich RP. Inactivation of viruses in blood products (platelets, plasma, and red cells). Transfus Clin Biol 2001 8 : 103S.
5. Kumar V, Motheral T, Luzniak G, Goodrich RP. Mirasol pathogen reduction technology: riboflavin-based plasma process inactivates intracellular and extracellular human immunodeficiency virus. J Clin Apheresis 2003 18 : 84.
6. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004 44 : 877 85.
7. Chernoff A, Snyder EL. The cellular and molecular basis of the platelet storage lesion: a symposium summary. Transfusion 1992 32 : 386 90.
8. Li J, Goodrich L, Hansen E, Edrich E, Gampp D, Goodrich RP. Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage. Transfusion 2005 45 : 1750 8.
9. Bertolini F, Murphy S. A multicenter evaluation of reproducibility of swirling in platelet concentrates. Biochemical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion. Transfusion 1994 34 : 798 801.
10. Holme S, Moroff G, Murphy S. A multi-laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Biochemical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Transfusion 1998 38 : 31 40.
11. Bode AP. Platelet activation may explain the storage lesion in platelet concentrates. Blood Cells 1990 16 : 109 25.
12. Li J, De Korte D, Woolum MD, Ruane PH, Keil SD, Lockerbie O, McLean R, Goodrich RP. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004 87 : 82 90.
13. Li J, Xia Y, Bertino AM, Coburn JP, Kuter DJ. The mechanism of apoptosis in human platelets during storage. Transfusion 2000 40 : 1320 9.
14. Perrotta PL, Perrotta CL, Snyder EL. Apoptotic activity in stored human platelets. Transfusion 2003 43 : 526 35.
15. Murphy S. Utility of in vitro tests in predicting the in vivo viability of stored PLTs. Transfusion 2004 44 : 618 9.
16. Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004 44 : 320 9.
17. Guidelines for the collection of blood and blood components and the usage of blood products (hemotherapy). Rev. ed., German Medical Association and Paul-Ehrlich-Institute. Cologne: Deutscher Ärzteverlag 2005.
18. Council of Europe. Guide to the preparation, use and quality assurance of blood components. 13th ed. Strasbourg, France : Council of Europe Publishing 2007.
19. Li J, Lockerbie O, De Korte D, Rice J, McLean R, Goodrich RP. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005 45 : 920 6.
20. Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, Li J, Goodrich R, Escolar G. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005 45 : 911 9.
21. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns AP. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006 90 : 279 85.
22. Darzynkiewicz Z, Bedner E, Smolewski P. Flow cytometry in analysis of cell cycle and apoptosis. Semin Hematol 2001 38 : 179 93.
23. Kilkson H, Holme S, Murphy S. Platelet metabolism during storage of platelet concentrates at 22°C. Blood 1984 64 : 406 14.
24. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005 45 : 1335 41.
25. Janetzko K, Klinger M, Mayaudon V., Lin L, Eichler H, Klüter H. Storage characteristics of split double-dose platelet concentrates derived from apheresis and treated with amotosalen-HCl and UVA light for pathogen inactivation. Infus Ther Transfus Med 2002 29 : 193 8.
26. Rhenen van DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy-coats. Vox Sang 2000 79 : 206 14.
27. Hagberg IA, Akkøk CA, Lyberg T, Kjeldsen-Kragh J. Apheresis-induced platelet activation: comparison of three types of cell separators. Transfusion 2000 40 : 182 92.
28. Holme S, Sweeney JD, Sawyer S, Elfath MD. The expression of P-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion 1997 37 : 12 7.
29. Gorlin JB. Standards for blood banks and transfusion services. 21st ed. Bethesda, MD : American Association of Blood Banks 2002.
30. Holme S. Effect of additive solutions on platelet biochemistry. Blood Cells 1992 18 : 421 30.
31. van der Meer PF, Pietersz RN, Reesink HW. Storage of platelets in additive solution for up to 12 days with maintenance of good in-vitro quality. Transfusion 2004 44 : 1204 11.
32. Adams GA, Rock G. Storage of human platelet concentrates in an artificial medium without dextrose. Transfusion 1988 28 : 217 20.
33. Murphy S. Principles for storage of platelet concentrates. Infusionstherapie 1991 18 : 3 9.
34. Guppy M, Whisson ME, Sabaratnam R, Withers P, Brand K. Alternative fuels for platelet storage: a metabolic study. Vox Sang 1990 59 : 146 52.
35. Shimizu T, Murphy S. Roles of acetate and phosphate in the successful storage of platelet concentrates prepared with an acetate-containing additive solution. Transfusion 1993 33 : 304 10.
36. Cesar J, DiMinno G, Alam I, Silver M, Murphy S. Plasma free fatty acid metabolism during storage of platelet concentrates for transfusion. Transfusion 1987 27 : 434 7.
37. Gulliksson H. Additive solutions for the storage of platelets for transfusion. Transfus Med 2000 10 : 257 65.
38. Snyder EL, Beardsley DS, Smith BR. Storage of platelet concentrates after high-dose ultraviolet B irradiation. Transfusion 1991 31 : 491 6.
39. Gawaz MP. Blood platelets. New York : Georg Thieme Verlag Stuttgart 2001.
40. Muenzer J, Weinbach EC, Wolfe SM. Oxygen consumption of human blood platelets. Effect of inhibitors on thrombin-induced oxygen burst. Biochim Biophys Acta 1975 376 : 243 8.
41. Kirtland SJ, Baum H. Mitochondrial respiration and the thrombin-induced release reaction of platelets. Biochem Pharmacol 1974 23 : 1859 70.
42. Muenzer J, Weinbach EC, Wolfe SM. Oxygen consumption of human blood platelets. Effect of thrombin. Biochim Biophys Acta 1975 376 : 237 42.
43. Pickett WC, Cohen P. Mechanism of the thrombin-mediated burst in oxygen consumption by human platelets. J Biol Chem 1976 251 : 2536 8.
44. Mürer EH. Release reaction and energy metabolism in blood platelets with special reference to the burst in oxygen uptake. Biochim Biophys Acta 1968 162 : 320 6.
45. Rognoni F, Viganò V, Colombo Pirola L. Influence of platelet anti-aggregants on mitochondrial respiration of platelets. Boll Soc Ital Cardiol 1977 22 : 2140 6.
46. Abou-Khalil S, Abou-Khalil WH, Yunis AA. Mechanism of interaction of ticlopidine and its analogues with the energy-conserving mechanism in mitochondria. Biochem Pharmacol 1986 35 : 1855 9.
47. Abou-Khalil WH, Lim LO, Yunis AA, Abou-Khalil S. Effects of ticlopidine, a new platelet antiaggregating agent, and its analogues on mitochondrial metabolism. Oxidative phosphorylation, protein synthesis and DNA polymerase activity. Biochem Pharmacol 1984 33 : 3893 8.
48. Lin JS, Tzeng CH, Hao TC, Hu HY, Tsai YC, Lin CP, Yung CH. Influence of gamma irradiation and storage on apheresis platelets. J Formos Med Assoc 2001 100 : 101 5.